Abstract The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue in a field that has historically relied on symptom relief, rather than survival benefit or modification of disease course, as key response criteria. There is, therefore, a need to understand what constitutes disease modification of myelofibrosis to advance appropriate drug […]
Momelotinib: emerging treatment for myelofibrosis patients with anemia
Abstract The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways, resulting in decreased hepcidin (master iron regulator) expression, higher serum iron and hemoglobin levels, and restored erythropoiesis. Clinical data on momelotinib from the phase 2 and the […]
Clinical Trial Update on Emerging MPN Treatments
by David Wallace Find out the latest news on Ropeginterferon and PTG-300 for treating polycythemia vera, as well as the most promising new treatments for myelofibrosis. What’s the clinical significance of the Allele Burden (AB)? Are there common elements between COVID-19 and MPN…should you get the vaccine? Learn more as Dr. Srdan Verstovsek, Professor, Department of […]
